CN110167550A - 西克里维罗甲磺酸盐的固体形式及其制备方法 - Google Patents

西克里维罗甲磺酸盐的固体形式及其制备方法 Download PDF

Info

Publication number
CN110167550A
CN110167550A CN201780061529.6A CN201780061529A CN110167550A CN 110167550 A CN110167550 A CN 110167550A CN 201780061529 A CN201780061529 A CN 201780061529A CN 110167550 A CN110167550 A CN 110167550A
Authority
CN
China
Prior art keywords
msoh
compound
crystalline form
acetonitrile
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780061529.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·菲亚芳萨
M·I·库珀
E·K·夏普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of CN110167550A publication Critical patent/CN110167550A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780061529.6A 2016-08-31 2017-08-30 西克里维罗甲磺酸盐的固体形式及其制备方法 Pending CN110167550A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
US62/382,153 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
CN110167550A true CN110167550A (zh) 2019-08-23

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780061529.6A Pending CN110167550A (zh) 2016-08-31 2017-08-30 西克里维罗甲磺酸盐的固体形式及其制备方法

Country Status (13)

Country Link
US (1) US10301287B2 (enExample)
EP (1) EP3506896A4 (enExample)
JP (2) JP2019526628A (enExample)
KR (1) KR20190057066A (enExample)
CN (1) CN110167550A (enExample)
AU (1) AU2017321594A1 (enExample)
BR (1) BR112019003987A2 (enExample)
CA (1) CA3034606A1 (enExample)
MX (1) MX2019002057A (enExample)
RU (1) RU2019109019A (enExample)
SG (1) SG11201901438VA (enExample)
TW (1) TW201823235A (enExample)
WO (1) WO2018045043A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245518A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245535A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
EP3844209B1 (en) * 2018-08-31 2022-06-22 Evonik Operations GmbH Process for preparing a polymer powder
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
WO2021233349A1 (zh) 2020-05-22 2021-11-25 南京明德新药研发有限公司 吡啶类衍生物及其应用
WO2022177014A1 (ja) * 2021-02-22 2022-08-25 旭化成株式会社 セルロースナノファイバーを含む組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
CN1282243A (zh) 1997-12-19 2001-01-31 武田药品工业株式会社 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
WO2001017947A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
EP1484322A4 (en) 2002-03-12 2008-01-23 Takeda Pharmaceutical PROCESS FOR PRODUCING AN OPTICALLY ACTIVE SULFOXIDE DERIVATIVE
US20080249147A1 (en) 2004-03-24 2008-10-09 Takeda Pharmaceutical Company Limited Emulsion-Stabilized Preparation
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
PE20140406A1 (es) 2010-11-18 2014-04-16 Univ Yale Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana
EP2846788A1 (en) * 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
UA115807C2 (uk) 2013-05-15 2017-12-26 Тобіра Терап'Ютикс, Інк. Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти)
RU2020119611A (ru) 2014-03-21 2020-06-29 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
US20170105969A1 (en) 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
CN112266392A (zh) * 2014-12-23 2021-01-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法

Also Published As

Publication number Publication date
BR112019003987A2 (pt) 2019-05-28
MX2019002057A (es) 2019-11-18
US20180057481A1 (en) 2018-03-01
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18
JP2019526628A (ja) 2019-09-19
RU2019109019A3 (enExample) 2021-08-23
TW201823235A (zh) 2018-07-01
JP2022137223A (ja) 2022-09-21
EP3506896A4 (en) 2020-08-26
SG11201901438VA (en) 2019-03-28
WO2018045043A1 (en) 2018-03-08
US10301287B2 (en) 2019-05-28
KR20190057066A (ko) 2019-05-27
CA3034606A1 (en) 2018-03-08
EP3506896A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
CN110167550A (zh) 西克里维罗甲磺酸盐的固体形式及其制备方法
JP6081763B2 (ja) ダサチニブ多形体およびその調製プロセス
JP7199739B2 (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
EP3344607B1 (en) Solid state forms of selexipag
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
EP3565819B1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2018022704A1 (en) Crystalline form vi of selexipag
WO2018233591A1 (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
US9212172B2 (en) Preparation of crystalline bazedoxifene and its salts
US11434204B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
WO2023143576A1 (zh) 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式
US20160122274A1 (en) Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
RU2792728C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ 3-[5-АМИНО-4-(3-ЦИАНОБЕНЗОИЛ)ПИРАЗОЛ-1-ил]-N-ЦИКЛОПРОПИЛ-4-МЕТИЛБЕНЗАМИДА
TW202434600A (zh) 磺醯胺衍生物結晶形式及其製備方法
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
TW202140493A (zh) 2-吲哚啉螺環酮類化合物或其鹽、溶劑錯合物之非晶形式或結晶形式
HK40001929A (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
HK40001929B (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190823

WD01 Invention patent application deemed withdrawn after publication